CHOLANGIOCARCINOMA

This study tests two immunotherapy drugs, nivolumab and ipilimumab, in adults with over 50 types of rare cancers. The goal is to see if this drug combination can shrink tumors or stop them from growing. The trial is no longer enrolling new participants, but results will help guid…

This study tests an experimental drug called CGT4859 in people with bile duct cancer or other advanced solid tumors that have certain genetic changes (FGFR2 or FGFR3). The goal is to find the best dose and see if the drug can shrink tumors or slow their growth. About 110 adults w…

This study tests an experimental drug called entrectinib in people with advanced solid tumors that have certain gene changes (NTRK, ROS1, or ALK). The drug aims to shrink or control the cancer by blocking signals that help it grow. About 534 adults with various cancers, including…

This study tests the drug pembrolizumab in about 1,600 people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug can shrink tumors and to identify biomarkers that predict response. Participants receive pembrolizumab and are m…

This early-stage study tests an oral drug called LY3410738 in people with advanced solid tumors that have IDH1 or IDH2 gene mutations, including bile duct cancer, cartilage cancer, and brain tumors. The main goals are to find the best dose and check safety. About 200 participants…

This study tests whether adding the experimental drug CTX-009 to standard chemotherapy (paclitaxel) helps adults with advanced bile duct, gallbladder, or ampullary cancer that has worsened after one prior treatment. About 168 participants will be randomly assigned to receive eith…

This study tests whether adding the drug tucatinib to standard treatments (like trastuzumab and chemotherapy) is safe for people with HER2-positive cancers of the digestive system. About 40 adults with advanced cancer of the colon, stomach, esophagus, or gallbladder will receive …

This study aimed to see if a person's own immune cells, modified in a lab to target specific cancer gene mutations, could prevent gastrointestinal cancers from coming back after standard treatment. It was designed for people with certain gene changes and blood markers suggesting …

This study was designed to compare two different needles used to take tissue samples from solid masses in the pancreas and digestive tract. The goal was to see which needle provides more accurate diagnosis of cancer. However, the study was withdrawn before any participants were e…

This early-phase trial studies the safety and best dose of radiation therapy for people with liver cancer (hepatocellular carcinoma, cholangiocarcinoma, or cancer that spread to the liver) who also have liver damage from cirrhosis, chemotherapy, or surgery. About 36 participants …

This study is for adults with liver cancer who have had or plan to have immunotherapy. Researchers will collect blood, urine, stool, and tissue samples, along with medical records, to build a large database. The goal is to learn more about how liver cancer develops and responds t…

This early-phase study tests a new imaging tracer called 68Ga-FAPI-46 in 26 people with various cancers. The tracer targets cells around tumors, helping PET scans show where cancer is located. Researchers want to see how well the tracer works and compare it to standard imaging. T…

This study looks at whether a home-based exercise program is practical and safe for people aged 65 and older who are waiting for liver or bile duct cancer surgery. About 25 participants will be asked to follow a moderate exercise routine and attend virtual training sessions. The …

This study tests a new blood test to find early signs of bile duct cancer coming back or getting worse. About 100 adults with suspected or confirmed bile duct cancer who are planning surgery will give blood samples before and after treatment. The goal is to see if certain markers…